Prevalence of, Evolution of, and Risk Factors for Fat Atrophy and Fat Deposition in a Cohort of HIV-Infected Men and Women
Open Access
- 15 June 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 40 (12) , 1837-1845
- https://doi.org/10.1086/430379
Abstract
Background. At present, no uniform definition of human immunodeficiency virus (HIV)–associated lipoatrophy exists. The risk factors for fat atrophy (Keywords
This publication has 36 references indexed in Scilit:
- HIV lipodystrophy: prevalence, severity and correlates of risk in AustraliaHIV Medicine, 2003
- Incidence of and Risk Factors for Lipoatrophy (Abnormal Fat Loss) in Ambulatory HIV-1-Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Incidence of Adipose Tissue Alterations in First-Line Antiretroviral TherapyArchives of internal medicine (1960), 2002
- The prevalence of lipodystrophy in an ambulant HIV‐infected population: it all depends on the definitionHIV Medicine, 2001
- Stavudine Versus Zidovudine and the Development of LipodystrophyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort studyPublished by Elsevier ,2001
- Lipodystrophy, Metabolic Disorders, and Human Immunodeficiency Virus Infection: Aquitaine Cohort, France, 1999Clinical Infectious Diseases, 2000
- Lipoatrophy, Fat Accumulation, and Mixed Syndrome in Protease Inhibitor???Naive HIV-Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort studyThe Lancet, 1999
- Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapyAIDS, 1999